Navigation Links
Schering-Plough Announces Changes to its Global Collaboration with Novartis to Develop Combination Therapies for Asthma and COPD
Date:5/18/2009

gredients in ASMANEX. There have been cases of hypersensitivity, allergic reactions, facial swelling, hives, and throat tightness reported.

Patients who use inhaled steroid medicines for asthma may develop a fungal infection of the mouth and throat. Rinse your mouth after using ASMANEX.

It is possible that hypercorticism (an excess level of steroids in your body) or adrenal insufficiency (your adrenal gland cannot produce enough steroids) may appear in a small number of patients, particularly when ASMANEX is administered at higher than recommended doses over prolonged periods of time. If such effects occur, consult your health care provider as the dosage of ASMANEX should be reduced slowly.

If you or your child took steroids by mouth and are having them decreased or are being switched to ASMANEX, you should be followed closely by your health care provider and the oral steroids should be reduced slowly. Deaths due to adrenal insufficiency have occurred during and after switching from oral steroids to inhaled steroids. Tell your health care provider right away about any symptoms such as feeling tired or exhausted, weakness, nausea, vomiting, or symptoms of low blood pressure (such as dizziness or faintness). If you or your child is under stress, such as with surgery, after surgery, or trauma, you may need steroids by mouth again.

Avoid coming in contact with measles, chicken pox virus, tuberculosis, or any other infections before or while using ASMANEX. Contact your health care provider immediately if you or your child have been exposed.

Patients who use inhaled steroids, including ASMANEX, for a long time may have an increased risk of decreased bone mass, which can affect bone strength. Patients who are at increased risk of decreased bone mass should be monitored.

Inhaled steroids, including ASMANEX, may cause a reduction in growth velocity when administered to pedia
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Schering-Plough Schedules Webcast For Annual Meeting of Shareholders
2. Schering-Plough Schedules Conference Call Webcast for 2009 First Quarter Earnings
3. Schering-Plough to Webcast Presentation at Barclays Capital Global Healthcare Conference
4. Video: Schering-Plough Introduces AFRIN(R) PureSea(TM): A Natural, Gentle Nasal Rinse From the Seas of Northern France
5. Novartis/Schering-Ploughs Drug Will Replace AstraZenecas Symbicort as Decision Resources Clinical Gold Standard by 2012 for the Treatment of Asthma
6. Schering-Plough Announces Collaboration With World Health Organization to Provide Access to Pandemic Influenza Vaccine Technology to Developing Countries
7. Schering-Plough Submits Response to FDA for SAPHRIS(TM) (asenapine) in the Acute Treatment of Both Schizophrenia and Bipolar I Disorder
8. Schering-Plough to Webcast Presentation at 27th Annual J.P. Morgan Healthcare Conference
9. HUYA Bioscience Announces Agreement to Provide Schering-Plough With Drug Development Candidates From China
10. Schering-Plough Declares Quarterly Dividends on Common Shares and 2007 Mandatory Convertible Preferred Stock
11. Schering-Plough Reschedules Time of Conference Call, Webcast for 2008 Second Quarter Earnings to Later Today
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... July 30, 2015 AACC welcomed thousands ... 2015 AACC Annual Meeting & Clinical Lab Expo ... 26–30. The meeting showcased revolutionary advancements in clinical ... of healthcare providers to diagnose patients quickly and ... treatment. As of Wednesday, July ...
(Date:7/30/2015)... ... July 30, 2015 , ... ... Francois Vieillard as Sales & Marketing Director. , With more than 25 ... be responsible for reinforcing Tronics’ business development activities worldwide. He brings to the ...
(Date:7/30/2015)... July 30, 2015 According to ... (Software, Molecular Modeling, PB/PK, PKPD, Trial Design, Toxicity Prediction, ... Preclinical, Clinical Trial), by End Users - Global Forecast ... expected to reach USD 2,107.99 million by 2020 from ... 15.29%. Browse more than ...
(Date:7/30/2015)... 30, 2015   Aratana Therapeutics, Inc . ... focused on the licensing, development and commercialization of ... that its strategic partner VetStem Biopharma, Inc. has ... of AT-016, an adipose-derived allogeneic stem cell product ... osteoarthritis pain in dogs. The double-blinded, ...
Breaking Biology Technology:Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 2Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 3Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 4Tronics appoints Francois Vieillard as Sales and Marketing Director 2Biosimulation Market Worth 2,107.99 Million USD by 2020 2Biosimulation Market Worth 2,107.99 Million USD by 2020 3Biosimulation Market Worth 2,107.99 Million USD by 2020 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 5
... , May 13 /PRNewswire-Asia/ -- A signing ceremony for ... (TJAB) and Genzyme Corporation was held in the,Tianjin Economic-Technological Development Area ... , , ... Zihe, President of TJAB and,President of Nankai University, He Shushan, Director ...
... TRIANGLE PARK, N.C. , May 13 ... today announced the commencement of a first-in-human study of ... with in vitro activity against both tenofovir-sensitive ... potential to increase efficacy and decrease toxicity as compared ...
... Repligen Corporation (Nasdaq: RGEN ) announced today ... with the Food and Drug Administration (FDA) for a Phase ... inhibitor.  This is a double-blind, single ascending dose, Phase 1 ... profile of RG2833 in up to 40 subjects.  This study ...
Cached Biology Technology:Tianjin International Joint Academy of Biotechnology and Medicine, Genzyme Enter into Strategic Partnership 2Chimerix Initiates Phase 1 Study of CMX157 2Chimerix Initiates Phase 1 Study of CMX157 3Repligen Files Investigational New Drug Application with FDA for First Drug Targeting the Core Genetic Defect of Friedreich's Ataxia 2Repligen Files Investigational New Drug Application with FDA for First Drug Targeting the Core Genetic Defect of Friedreich's Ataxia 3Repligen Files Investigational New Drug Application with FDA for First Drug Targeting the Core Genetic Defect of Friedreich's Ataxia 4
(Date:7/31/2015)... , 31 de julio de 2015 ... (ICG-10,  www.icg-10.org ) del 22 al 25 de octubre ... La conferencia celebra su décimo aniversario este ... convertido en una de las reuniones anuales más influyentes ... es una de las conferencias científicas más dinámicas, entusiastas ...
(Date:7/31/2015)... 2015 La 10e Conférence internationale sur ... par le BGI du 22 au 25 octobre ... Chine. La conférence célèbre son 10e ... l,ICG est devenue l,une des réunions annuelles mondiales ... et c,est aussi la plus dynamique, la plus ...
(Date:7/31/2015)... China , 31. Juli 2015 Die 10. ... wird von BGI veranstaltet und findet vom 22. ... China , statt. Die ... Seit ihrem Start 2006 ist die ICG weltweit ... „omik" geworden. Sie ist eines der dynamischsten, enthusiastischsten ...
Breaking Biology News(10 mins):La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 2La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 3Die 10. internationale Konferenz zu Genomik (ICG-10) beginnt im Oktober 2Die 10. internationale Konferenz zu Genomik (ICG-10) beginnt im Oktober 3
... straight to the uncovered food in your kitchen? Now ... over proportionally huge distances, using just very poor eyesight ... have significant benefits in the development of autonomous robots ... processes. , Scientists at the University of Sussex, ...
... the same metabolic disorders that have led to an epidemic ... of research conducted at Penn State University that are due ... the Proceedings of the National Academy of Science and also ... on 21 November. The discovery expands the known taxonomic ...
... heart failure and other health conditions, blood draws and diagnostic ... though, chemical or physiologic changes silently cause damage that is ... the future a tiny device, one the size of a ... to monitor and detect abnormalities, and could then relay data ...
Cached Biology News:How ants find their way 2Dragonfly's metabolic disease provides clues about human obesity 2Dragonfly's metabolic disease provides clues about human obesity 3Dragonfly's metabolic disease provides clues about human obesity 4Dragonfly's metabolic disease provides clues about human obesity 5Cardiologist's 'living chip' changes science of disease monitoring 2Cardiologist's 'living chip' changes science of disease monitoring 3Cardiologist's 'living chip' changes science of disease monitoring 4
...
... Although the mixed TAMRA isomers are ... isomers are increasingly preferred for labeling peptides ... in HPLC purification that is often required ... often used than 6-TAMRA for labeling peptides ...
Rabbit polyclonal to GPCR G2A ( Abpromise for all tested applications). entrezGeneID: 29933 SwissProtID: Q9UNW8...
Alkali soluble casein is the recommended blot blocking reagent for use with the HisTag Monoclonal Antibody (Novagen) on Western blots....
Biology Products: